Pretax income is the income that a company earns before paying income taxes. Esperion Therapeutics's pretax income for the
three
months ended in Dec. 2023 was $-56.3 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was $-209.2 Mil.
Esperion Therapeutics's pretax margin was -174.71%.
During the past 13 years, Esperion Therapeutics's highest Pretax Margin was -63.09%. The lowest was -343.04%. And the median was -179.87%.
Esperion Therapeutics Pre-Tax Income Historical Data
The historical data trend for Esperion Therapeutics's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Esperion Therapeutics's Pre-Tax Income
For the Drug Manufacturers - Specialty & Generic subindustry, Esperion Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Esperion Therapeutics's Pre-Tax Income Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Esperion Therapeutics's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Esperion Therapeutics's Pre-Tax Income falls into.
Esperion Therapeutics Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
Esperion Therapeutics's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-209.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Esperion Therapeutics (NAS:ESPR) Pre-Tax Income Explanation
Esperion Therapeutics's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as
During the past 13 years, Esperion Therapeutics's highest Pretax Margin was -63.09%. The lowest was -343.04%. And the median was -179.87%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Esperion Therapeutics Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Esperion Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Esperion Therapeutics (Esperion Therapeutics) Business Description
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ESPR has been successfully added to your 